BLTE — Belite Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $4.61bn
- $4.61bn
- 46
- 21
- 60
- 37
Annual cashflow statement for Belite Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.75 | -9.67 | -12.6 | -31.6 | -36.1 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 1.36 | 1.52 | 1.62 | 4.08 | 5.61 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.069 | 0.64 | -0.491 | -2.43 | 1.13 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -4.44 | -7.47 | -11.5 | -29.8 | -29.2 |
| Capital Expenditures | 0 | -0.074 | -0.394 | -0.063 | -0.151 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.02 | 0.018 | 0 | 0 | -110 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.02 | -0.056 | -0.394 | -0.063 | -111 |
| Financing Cash Flow Items | 0 | -0.815 | -1.03 | 54 | 41.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 28.1 | -0.583 | 37 | 76 | 83.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 23.6 | -8.27 | 24.7 | 46.1 | -56.5 |